Philipp Schommers

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Tularaemia after deer exposure in a vehicular collision.

Tularaemia after deer exposure in a vehicular collision.

Journal: The Lancet. Infectious diseases

Published: April 25, 2026

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

Journal: iScience

Published: March 10, 2026

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Journal: Blood advances

Published: December 05, 2025

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Journal: Blood advances

Published: December 05, 2025

Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope.

Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope.

Journal: bioRxiv : the preprint server for biology

Published: September 18, 2025

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope.

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope.

Journal: Nature immunology

Published: May 15, 2025

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Journal: Nature immunology

Published: March 06, 2025

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Journal: Nature immunology

Published: March 06, 2025

Clinical heterogeneity and treatment outcomes of extrapulmonary tuberculosis in a low-incidence setting: insights from a prospective cohort study.

Clinical heterogeneity and treatment outcomes of extrapulmonary tuberculosis in a low-incidence setting: insights from a prospective cohort study.

Journal: Infection

Published: December 06, 2024

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation.

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation.

Journal: Nature

Published: November 28, 2024

Therapeutic interfering particles against HIV: molecular parasites reducing viremia.

Therapeutic interfering particles against HIV: molecular parasites reducing viremia.

Journal: Signal transduction and targeted therapy

Published: September 04, 2024

Showing 1-12 of 72

Last Updated: 09/26/2026